DPHARMA | DUOPHARMA BIOTECH BHD
1.52 (0.66%)
T-O (am): 1.50 (08:59:00)
Last updated: 16:59
Fundamental
Technical
Total Score
iSaham Fundamental Trend
FCON: | Sharpe Ratio: | LTS:
Quarter Reports
Select columns required and click "Update" to save your preferences
| Ann. Date | Qtr. Date | Q | FYE | Revenue [M] | PBT [M] | NP [M] | NPM | DPS | EPS | R. QoQ | R. YoY | E. QoQ | E. YoY | TTM EPS |
Adj. [M] |
NP [M] (adj) |
NPM (adj) |
EPS (adj) |
E. QoQ (adj) |
E. YoY (adj) |
TTM EPS (adj) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 Feb 23 | Q4 Dec 22 | 4 | 31 Dec 22 | 151.96 | 15.35 | 17.16 | 11.3% | 1.80 | 1.80 | 14.2% | 4.5% | 5.0% | 9.2% | ||||||||
| 09 Nov 22 | Q3 Sep 22 | 3 | 31 Dec 22 | 177.07 | 21.39 | 16.35 | 9.2% | 0.00 | 1.72 | 2.6% | 3.0% | 0.2% | 3.6% | ||||||||
| 16 Aug 22 | Q2 Jun 22 | 2 | 31 Dec 22 | 181.74 | 21.47 | 16.31 | 9.0% | 0.50 | 1.72 | 2.3% | 16.9% | 19.6% | 6.0% | ||||||||
| 17 May 22 | Q1 Mar 22 | 1 | 31 Dec 22 | 185.94 | 26.65 | 20.29 | 10.9% | 0.00 | 2.19 | 27.8% | 11.7% | 29.1% | 15.2% | ||||||||
| 15 Feb 22 | Q4 Dec 21 | 4 | 31 Dec 21 | 145.44 | 17.13 | 15.72 | 10.8% | 1.80 | 1.67 | 15.4% | 8.5% | 7.3% | 3.0% | ||||||||
| 18 Nov 21 | Q3 Sep 21 | 3 | 31 Dec 21 | 171.84 | 22.48 | 16.96 | 9.9% | 0.00 | 1.80 | 10.6% | 28.5% | 10.2% | 20.1% | ||||||||
| 17 Aug 21 | Q2 Jun 21 | 2 | 31 Dec 21 | 155.44 | 20.20 | 15.39 | 9.9% | 0.50 | 2.18 | 6.6% | 8.4% | 12.6% | 4.5% | ||||||||
| 03 May 21 | Q1 Mar 21 | 1 | 31 Dec 21 | 166.45 | 23.18 | 17.61 | 10.6% | 0.00 | 2.49 | 24.1% | 4.9% | 8.8% | 29.9% | ||||||||
| 22 Feb 21 | Q4 Dec 20 | 4 | 31 Dec 20 | 134.09 | 20.47 | 16.19 | 12.1% | 6.00 | 2.29 | 0.2% | 2.7% | 14.6% | 34.6% | ||||||||
| 12 Nov 20 | Q3 Sep 20 | 3 | 31 Dec 20 | 133.77 | 18.57 | 14.13 | 10.6% | 0.00 | 2.03 | 6.7% | 6.4% | 4.1% | 4.9% | ||||||||
| 13 Aug 20 | Q2 Jun 20 | 2 | 31 Dec 20 | 143.33 | 19.39 | 14.73 | 10.3% | 0.50 | 2.15 | 9.7% | 1.5% | 8.6% | 5.8% | ||||||||
| 18 May 20 | Q1 Mar 20 | 1 | 31 Dec 20 | 158.71 | 17.73 | 13.56 | 8.5% | 0.00 | 1.98 | 15.2% | 5.5% | 12.7% | 6.2% | ||||||||
| 13 Feb 20 | Q4 Dec 19 | 4 | 31 Dec 19 | 137.75 | 13.94 | 12.03 | 8.7% | 5.00 | 1.76 | 3.6% | 19.1% | 19.0% | 16.3% | ||||||||
| 29 Nov 19 | Q3 Sep 19 | 3 | 31 Dec 19 | 142.85 | 19.77 | 14.86 | 10.4% | 0.00 | 2.20 | 1.8% | 13.5% | 6.8% | 20.9% | ||||||||
| 30 Aug 19 | Q2 Jun 19 | 2 | 31 Dec 19 | 145.47 | 18.32 | 13.92 | 9.6% | 1.00 | 2.07 | 3.3% | 17.3% | 3.8% | 34.6% | ||||||||
| 21 May 19 | Q1 Mar 19 | 1 | 31 Dec 19 | 150.39 | 18.79 | 14.46 | 9.6% | 0.00 | 2.19 | 30.1% | 12.8% | 0.7% | 34.2% | ||||||||
| 18 Feb 19 | Q4 Dec 18 | 4 | 31 Dec 18 | 115.63 | 17.66 | 14.37 | 12.4% | 4.00 | 2.17 | 8.1% | 3.0% | 16.9% | 21.1% | ||||||||
| 28 Nov 18 | Q3 Sep 18 | 3 | 31 Dec 18 | 125.84 | 15.84 | 12.29 | 9.8% | 0.00 | 1.86 | 1.5% | 9.1% | 18.8% | 7.7% | ||||||||
| 26 Nov 18 | Q2 Jun 18 | 2 | 31 Dec 18 | 123.99 | 12.91 | 10.34 | 8.3% | 1.50 | 1.59 | 7.0% | 5.9% | 4.1% | 7.1% | ||||||||
| 28 May 18 | Q1 Mar 18 | 1 | 31 Dec 18 | 133.26 | 13.26 | 10.78 | 8.1% | 0.00 | 3.82 | 18.7% | 8.1% | 9.2% | 12.7% | ||||||||
| 28 Feb 18 | Q4 Dec 17 | 4 | 31 Dec 17 | 112.25 | 12.82 | 11.87 | 10.6% | 6.00 | 4.22 | 2.7% | 51.6% | 4.1% | 19.6% | ||||||||
| 17 Nov 17 | Q3 Sep 17 | 3 | 31 Dec 17 | 115.38 | 14.21 | 11.40 | 9.9% | 0.00 | 3.99 | 1.4% | 43.7% | 18.1% | 79.9% | ||||||||
| 25 Aug 17 | Q2 Jun 17 | 2 | 31 Dec 17 | 117.05 | 12.64 | 9.65 | 8.2% | 2.50 | 3.46 | 5.1% | 47.9% | 0.9% | 114.4% | ||||||||
| 22 May 17 | Q1 Mar 17 | 1 | 31 Dec 17 | 123.31 | 12.12 | 9.56 | 7.8% | 0.00 | 3.43 | 66.6% | 55.2% | 3.6% | 21.9% | ||||||||
| 24 Feb 17 | Q4 Dec 16 | 4 | 31 Dec 16 | 74.03 | 6.30 | 9.93 | 13.4% | 0.04 | 3.41 | 7.8% | 17.2% | 56.5% | 35.3% | ||||||||
| 21 Nov 16 | Q3 Sep 16 | 3 | 31 Dec 16 | 80.30 | 7.52 | 6.34 | 7.9% | 0.00 | 2.23 | 1.5% | 1.2% | 40.8% | 26.5% | ||||||||
| 22 Aug 16 | Q2 Jun 16 | 2 | 31 Dec 16 | 79.14 | 7.72 | 4.50 | 5.7% | 2.50 | 1.41 | 0.4% | 40.5% | 42.6% | 23.0% | ||||||||
| 18 May 16 | Q1 Mar 16 | 1 | 31 Dec 16 | 79.47 | 9.94 | 7.84 | 9.9% | 0.00 | 2.81 | 11.1% | 74.3% | 48.9% | 12.6% | ||||||||
| 23 Feb 16 | Q4 Dec 15 | 4 | 31 Dec 15 | 89.40 | 17.53 | 15.34 | 17.1% | 5.50 | 9.19 | 12.6% | 75.2% | 77.8% | 37.9% | ||||||||
| 24 Nov 15 | Q3 Sep 15 | 3 | 31 Dec 15 | 79.37 | 11.62 | 8.62 | 10.9% | 0.00 | 5.17 | 41.0% | 77.1% | 47.5% | 0.7% | ||||||||
| 25 Aug 15 | Q2 Jun 15 | 2 | 31 Dec 15 | 56.31 | 8.41 | 5.85 | 10.4% | 4.00 | 4.19 | 23.5% | 38.6% | 34.8% | 22.2% | ||||||||
| 18 May 15 | Q1 Mar 15 | 1 | 31 Dec 15 | 45.60 | 12.20 | 8.97 | 19.7% | 0.00 | 6.43 | 10.6% | 12.6% | 19.3% | 7.2% | ||||||||
| 24 Feb 15 | 31/12/14 | 4 | 31/12/14 | 51.02 | 13.92 | 11.12 | 21.8% | 14.50 | 8.01 | 13.8% | 11.6% | 28.1% | 19.4% |
Historical Dividends
Financial Ratios
| EPS | 7.36 sen |
| Trailing PE (Sector Median: 16.1) | 20.6 |
| PEG | 1.45 |
| Altman Z | 1.4 |
| Beaver | 0.124 |
| Current Ratio | 2.06 |
| Debt-Equity (DE) Ratio | 0.86 |
| FCF Yield | 9.7 % |
| Revenue QoQ | -14.18 % |
| Revenue YoY | 4.48% |
| Profit QoQ | 4.97 % |
| Profit YoY | 9.19 % |
| Profit Margin (Sector Median: 5.1) | 10.06 % |
| ROE (ROIC: 7.38) | 10.7 % |
| Dividend Per Share (DPS) | 2.3 sen |
| Dividend Yield (DY) | 1.51 % |
Adjusted Financial Ratios
Ratios below have been recalculated after adjusting for One Off Gain/Loss detected from Quarterly reports
| EPS | |
| Trailing PE (Sector Median: 16.1) | |
| Profit QoQ | |
| Profit YoY | |
| Profit Margin (Sector Median: 5.1) | |
| ROE (ROIC: 10.73) | |
| Altman Z |
Fair Value
Weighted Average Fair Value:
| Discounted Cash Flow (DCF) 5% Growth | |
| Discounted Cash Flow (DCF) 10% Growth | |
| Relative Valuation | |
| Average Analysts FV based on 6 rating(s) |
| Graham Formula | |
| Graham Number | |
| Net Tangible Asset (NTA) | 0.69 | Consistent QR FV |
The Fair Value numbers are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The figures shown here should be taken as educational purposes only
Advanced Calculators
Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.
| Forward PE FV Calculator | |
| Latest Profit (adjusted) [M] | 17.16 |
| Expected Profit (Next QR) [M] | |
| Expected Profit (After QR above) [M] | |
| Expected Profit (After QR above) [M] | |
| Estimated Fair Value |
| Growth/Risk Fair Value Calculator | |
| Expected growth (%) | |
| Estimated downside / risk (%) | |
| Estimated New DCF Fair Value |
| Contract/Award Contribution Calculator | |
| Contract/Award Value (in Million) | |
| Estimated Contribution to Stock Price | |
| Estimated New DCF Fair Value |
| Profit-Based Calculator | |
| Expected Profit (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Revenue-Based Calculator | |
| Expected Revenue (M) | |
| for Year | |
| Estimated New DCF Fair Value |
| Market Pricing | |
| Expected Profit (M) | 461.63 |
| Expected Revenue (M) | 4254.63 |
| Expected Growth (%) | 31.0 |
The Fair Value calculated using this calculators are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The purpose of this tool is to help investor to quickly calculate their own expected Fair Value based on their own research
Directors Share Purchases (Beta)
No transaction in the last 2 months.
Summary
Market Cap: 1447 M.
Number of Shares: 952 M.
Adjusted Float: 49.6%.
Stock highly correlated with
K1 (90%)
ZELAN (89%)
APPASIA (88%)
ASIAPAC (88%)
Duopharma Biotech Berhad, formerly known as CCM Duopharma Biotech Berhad. Duopharma core competencies in the pharmaceutical industry include manufacturing, research and development, and commercialization and marketing of over 300 generic drugs, including Omesec and Prelica, as well as Consumer Healthcare (CHC) products such as CHAMPS, FLAVETTES, PROVITON, and Uphamol, which are well-known and accepted by consumers in Malaysia, the region, and around the world. With technological and commercialization agreements with trustworthy and powerful international partners, the Company has also ventured into the biosimilars space.Their headquarters is located in Kuala Lumpur, Malaysia.
Sectors: Consumer Products, Healthcare, Pharmaceuticals, Post MCO, Vaccine
Code: 7148
Website: http://duopharmabiotech.com/
Related Links: Bursa | Annual Report | Announcement
Warrant Info:
No warrants listed
Top Shareholdings
Updated on 31-Mar-2022
| Shareholder | Value (M) |
|---|---|
| Permodalan Nasional Berhad | 605.33 |
| Employees Provident Fund Board | 126.99 |
| Amanah Saham Malaysia | 69.91 |
| Amanah Saham Bumiputera | 51.18 |
| CIMB Bank Berhad | 41.08 |
| Billion Victory Sdn Bhd | 22.59 |
| Principal Dali Equity Growth Fund | 21.4 |
| Public Islamic Treasures Growth Fund | 15.12 |
| Manulife Investment Shariah Progress Fund | 12.98 |
| National Trust Fund | 11.58 |
| Manulife Investment Progress Fund | 8.29 |
| Manulife Investment Al-Fauzan | 8.1 |
| Prulink Equity Fund | 6.53 |
| Amanah Saham Malaysia 3 | 6.53 |
| Participating Fund | 5.61 |
| Great Eastern Life Assurance (Malaysia) Berhad | 5.22 |
| Manulife Insurance Berhad | 5.11 |
| Eastspring Investmentssmall-Cap Fund | 4.62 |
| Hong Leong Assurance Berhad | 3.89 |
| Ooi Keng Tan | 3.87 |
| Kenanga Shariah Growth Opportunities Fund | 3.68 |
| ASEAN Growth Fund | 3.45 |
| Wisdomtree Emerging Markets Smallcap Dividend Fund | 3.45 |
| Gibraltar BSN Aggressive Fund | 3.42 |
| Hong Leong MSIG Takaful Berhad | 2.63 |
| Abu Bakar Bin Suleiman | 2.53 |
Social
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.
This calculator uses Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.